Ascendis Pharma A/S (ASND) Earnings
Ascendis Pharma A/S is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $1.13. ASND has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -266.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.21 | $0.32 | +52.4% | $334M | -7.8% |
| Feb 11, 2026 | $-0.06 | $-0.64 | -966.7% | $288M | -1.5% |
| Nov 12, 2025 | $-0.41 | $-1.17 | -185.4% | $250M | -17.3% |
| Aug 7, 2025 | $-1.42 | $-0.93 | +34.5% | $186M | -20.2% |
| May 1, 2025 | $-1.56 | $-1.66 | -6.4% | $111M | -27.9% |
| Feb 12, 2025 | $-1.20 | $-0.68 | +43.3% | $180M | +43.6% |
| Nov 14, 2024 | $-1.83 | $-1.81 | +1.1% | $63M | -14.4% |
| Sep 3, 2024 | $-1.54 | $-2.05 | -33.1% | $39M | +3.0% |
| May 2, 2024 | $-1.62 | $-2.48 | -53.3% | $103M | +11.5% |
| Feb 7, 2024 | $-2.19 | $-1.66 | +24.1% | $151M | +36.3% |
| Aug 16, 2023 | $-3.09 | $-1.54 | +50.2% | $52M | — |
| Apr 27, 2023 | $-2.93 | $-2.18 | +25.6% | $37M | +41.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Good day and welcome to the first quarter Ascendance Pharma earnings conference call. Transcon PTH is approved in the U.S. and EU for hypoparathyroidism. Transcon TTH is approved in EU and UK for chronic hypoparathyroidism. Transcon TMP is approved in U.S. for achondroplasia in children. Transcon HGH is approved in U.S. for growth hormone deficiency. First quarter of 2026 had 10.5 cents, revenues growing rapidly, profitable. Diversified product portfolio, rapid revenue growth, expanding pipeline. UoPaths global revenue in Q1 reached 197 million euros. New patient enrollment in US Q1 in line with Q4 2025. Outside US, EUROPAT available in 35 countries. Growth disorder branch: one-weekly growth control schedule, EuroVal commercially available, UroPill shows compelling results. Skytover maintains consistent performance. Pipeline includes combination therapy for achondroplasia. Oncology: discontinued internal development of Transcon IL-2 beta garments. Partnerships: once-monkey Transcon Semiclutide with NovoNosis advancing, Arconis programs on track.
Guidance
For YorvaPath, expect continued steady underlying increase in patients on therapy and reversal of one-time factors seen in Q1 to drive strong growth sequentially in Q2. For Skytropha, expect stable revenue throughout the year following similar seasonal pattern to 2025. Regarding YubaWell, encouraged by early demand trends and look forward to sharing more on Q2 call. Plan to provide updated guidance after Q2 call.
Segment performance
EuroPath global revenue in Q1 was 197 million euros. Skytropa contributed 44 million euros in Q1. Total Q1 2026 revenue was 247 million euros. R&D expenses in Q1 were 59 million euro, down from 78 million euro in Q4 2025. SG&A expenses rose to 145 million Euro in Q1 2026 compared to 136 million Euro in Q4 2025. Total operating expenses for Q1 2026 were 204 million Euro and operating profit was €25 million, reflecting a 10% operating margin. Non-IFRS operating profit was €55 million, and non-IFRS operating margin was 22%. Net profit for Q1 2026 was €629 million, which included recognition of a €679 million deferred tax asset in the P&L. Non-IFRS net profit was €18 million, or €0.27 per share.
Analyst Q&A
Q: Jessica Fai of J.P. Morgan asked about estimating U.S. YorbiPath sales and U.S. versus ex-U.S. split.
A: Scott gave background on one-time event in Europe direct, Jay commented on reimbursement improvement.
Q: Bank of America asked about reauthorization rates and usage among physicians.
A: Jay said seeing continued traction across prescribers, no meaningful difference in reauthorization rates for re-auth vs new patient.
Q: Aaron Weber asked about splitting 15 million impact and view on UV Well ITC cases.
A: Jan commented on UofL's unmet medical need and confidence in it, said estimate on 15 million impact was rough.
Q: Gavin Clark-Gartner asked about Phase III ACON-CMP and growth hormone combo trial enrollment speed and discontinuation rates.
A: Jan said trial has extremely high retention, illustrating satisfaction.
Q: Lee Wozzeck asked about new patient growth and sharing new script number.
A: Jan said will continue to be transparent but wouldn't give specific new script number.
Q: Alex Thompson asked about potential impact of URV 60 micrograms being on label and dose caps.
A: Jan said they are enrolling in trial to evaluate dose titration, believe even at 30 micrograms has major benefit.
Q: Joe Schwartz asked about physicians' concerns on switching chondroplasia patients and UVL combination with Skytrova.
A: Jan said numbers speak for itself on physicians' willingness, couldn't promote combination therapy but said it happens.
Q: Ellie Merle of Barclays asked about UVL enrollments and initial population.
A: Jan said insight would develop in coming months, Jay added on types of patients seeing enrollments.
Q: Yung Chong asked about monotherapy for hypochondriplasia.
A: Jan said strategy for hypochondriplasia would be aligned with chondroplasia.
Q: Luca Esai asked about mechanics of free drug for repat and comment on AstraZeneca's phase three data.
A: Jan and Jay talked about free drug for patients with reimbursement disruption, Jan said hoped AstraZeneca's compound not approved.
Q: Maxwell Skor asked about proportion of patients initiating treatment at age two or older in oncology.
A: Jan talked about product profile and benefit beyond linear growth.
Q: Paul Troy asked about UVL prescriptions and utilization in below two years of age population.
A: Jan said need longer time to give meaningful answer on prescriptions and utilization.
Q: Cecilia Hernandez asked about capital allocation strategy.
A: Scott said key component is to invest in R&D and will provide more color after Q2 call